Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
The U.S. Food and Drug Administration is planning to warn that Johnson & Johnson’s one-dose COVID-19 vaccine can lead to an increased risk of a rare neurological condition known as Guillain-Barré syndrome. The warning does not involve the Moderna or Pfizer vaccines, which are much more widely used in the United States.
This will not help calm nerves or quiet vaccine doubters, though it could send a signal that the FDA is serious about ensuring the public knows about even small risks.
People familiar with the FDA’s plans tell The New York Times that even though the chances of developing the condition are low, recipients of the Johnson & Johnson vaccine are between three and five times more likely to develop the condition compared to the general population.